Kala Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Kala Pharmaceuticals
KALA Stock  USD 0.40  0.01  2.44%   
Kala Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Kala Pharmaceuticals' valuation are provided below:
Gross Profit
1.3 M
Market Capitalization
370.5 M
Enterprise Value Revenue
0.0421
Earnings Share
(5.73)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental ratios for Kala Pharmaceuticals, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Kala Pharmaceuticals last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. As of February 18, 2026, Market Cap is expected to decline to about 41.9 M. In addition to that, Enterprise Value is expected to decline to about 21.2 M

Kala Pharmaceuticals Total Revenue

3.89 Million

Check Kala Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kala Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4 M, Interest Expense of 4.7 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 16.28, Dividend Yield of 0.0 or PTB Ratio of 3.39. Kala financial statements analysis is a perfect complement when working with Kala Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Kala Stock
Check out the analysis of Kala Pharmaceuticals Correlation against competitors.
For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.

Kala Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets103.1 M63.8 M77.2 M
Slightly volatile
Short and Long Term Debt Total49.6 M37.1 M37.7 M
Slightly volatile
Other Current Liabilities8.7 M5.7 M6.6 M
Slightly volatile
Total Current Liabilities17.1 M19.5 M14.1 M
Slightly volatile
Property Plant And Equipment Net2.7 M2.8 M6.9 M
Pretty Stable
Current Deferred Revenue544.6 K573.3 K13.6 M
Very volatile
Accounts Payable686.1 K722.2 K1.4 M
Pretty Stable
Cash71.5 M58.9 M54.5 M
Slightly volatile
Non Current Assets Total2.9 M3.1 M10.6 M
Pretty Stable
Cash And Short Term Investments78.5 M58.9 M59.4 M
Slightly volatile
Net Receivables257.8 K271.4 K3.1 M
Pretty Stable
Common Stock Shares Outstanding6.7 M6.3 M1.7 M
Slightly volatile
Liabilities And Stockholders Equity103.1 M63.8 M77.2 M
Slightly volatile
Non Current Liabilities Total59.4 M30.1 M43.6 M
Slightly volatile
Other Current Assets2.4 M1.9 M1.8 M
Slightly volatile
Other Stockholder Equity821.4 M782.3 M320.9 M
Slightly volatile
Total Liabilities76.5 M49.6 M57.7 M
Slightly volatile
Total Current Assets87.4 M60.7 M65.8 M
Slightly volatile
Short Term Debt12.9 M12.3 M4.7 M
Slightly volatile
Common Stock6.6 K6.9 K16.3 K
Pretty Stable
Other Liabilities5.1 M4.9 M3 M
Slightly volatile
Other Assets504.7 K531.3 K5.3 M
Pretty Stable
Long Term Debt41.8 M23.1 M29.5 M
Slightly volatile
Short and Long Term Debt12.5 M11.9 M5.8 M
Slightly volatile
Property Plant Equipment454.5 K478.4 K5.1 M
Very volatile
Common Stock Total Equity71.2 K67.8 K31.5 K
Slightly volatile
Long Term Debt Total44.5 M83.1 M41.1 M
Slightly volatile
Capital Surpluse603.4 M574.7 M267.6 M
Slightly volatile
Property Plant And Equipment Gross3.2 M3.4 M7.3 M
Pretty Stable
Non Current Liabilities Other7.4 M4.2 M6.7 M
Slightly volatile
Net Invested Capital36.6 M38.5 M96 M
Slightly volatile
Net Working Capital30.6 M32.3 M87.4 M
Slightly volatile
Capital Lease Obligations1.6 M1.6 M19.4 M
Slightly volatile
Capital Stock5.1 K5.4 K28.7 K
Slightly volatile

Kala Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4 M3.8 M1.4 M
Slightly volatile
Interest Expense4.7 M6.7 M3.8 M
Slightly volatile
Other Operating Expenses61 M47.1 M47.5 M
Slightly volatile
Research Development21.2 M25.4 M17.7 M
Slightly volatile
Cost Of Revenue221.4 K233.1 K1.8 M
Very volatile
Total Operating Expenses59.8 M46.2 M46.5 M
Slightly volatile
Selling General Administrative41.9 M21.1 M29.2 M
Slightly volatile
Interest Income1.2 M2.4 M1.1 M
Slightly volatile
Non Recurring5.9 M9.9 M4.6 M
Slightly volatile
Reconciled Depreciation221.4 K233.1 K443.8 K
Pretty Stable

Kala Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation568.1 K297.9 K450.9 K
Slightly volatile
Capital Expenditures227.2 K239.2 K682.6 K
Pretty Stable
End Period Cash Flow75.2 M58.9 M57.1 M
Slightly volatile
Sale Purchase Of Stock398.8 K419.8 K24.5 M
Very volatile
Begin Period Cash Flow77 M58.5 M54.5 M
Slightly volatile
Stock Based Compensation8.5 M9.6 M5.8 M
Slightly volatile
Issuance Of Capital Stock45.2 M31.5 M61.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio16.2817.142.6 K
Slightly volatile
Days Sales Outstanding8757011 K
Slightly volatile
Stock Based Compensation To Revenue1.972.076.1536
Slightly volatile
Capex To Depreciation1.580.921.8577
Slightly volatile
EV To Sales8.559.02.6 K
Slightly volatile
Inventory Turnover0.350.430.342
Slightly volatile
Days Of Inventory On Hand1 K8851.2 K
Slightly volatile
Payables Turnover0.590.370.5723
Slightly volatile
Sales General And Administrative To Revenue33.4319.2246.0128
Slightly volatile
Research And Ddevelopement To Revenue4.965.2255.7512
Slightly volatile
Capex To Revenue0.08790.09254.1706
Slightly volatile
Cash Per Share10.1310.6673.085
Very volatile
Days Payables Outstanding1.1 K1 K1.4 K
Slightly volatile
Income Quality0.730.690.9076
Pretty Stable
Current Ratio4.032.84.1476
Slightly volatile
Receivables Turnover0.650.691.1399
Pretty Stable
Capex Per Share0.04120.04331.0178
Slightly volatile
Revenue Per Share3.122.33.8109
Slightly volatile
Interest Debt Per Share5.896.244.3398
Very volatile
Debt To Assets0.590.670.5701
Very volatile
Operating Cycle1.3 K7011.4 K
Slightly volatile
Days Of Payables Outstanding1.1 K1 K1.4 K
Slightly volatile
Ebt Per Ebit1.121.081.017
Pretty Stable
Quick Ratio3.972.84.0915
Slightly volatile
Cash Ratio3.542.723.6557
Pretty Stable
Days Of Inventory Outstanding1 K8851.2 K
Slightly volatile
Days Of Sales Outstanding8757011 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.161.0428
Very volatile
Fixed Asset Turnover8.848.422.9354
Slightly volatile
Debt Ratio0.590.670.5701
Very volatile
Price Sales Ratio16.2817.142.6 K
Slightly volatile
Asset Turnover0.0280.04030.0319
Slightly volatile
Gross Profit Margin0.590.390.5787
Slightly volatile

Kala Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap41.9 M44.1 M226.9 M
Slightly volatile
Enterprise Value21.2 M22.3 M211.1 M
Slightly volatile

Kala Fundamental Market Drivers

Kala Upcoming Events

1st of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
1st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Kala Pharmaceuticals Financial Statements

Kala Pharmaceuticals stakeholders use historical fundamental indicators, such as Kala Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Kala Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Kala Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Kala Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Kala Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue573.3 K544.6 K
Cost Of Revenue233.1 K221.4 K
Stock Based Compensation To Revenue 2.07  1.97 
Sales General And Administrative To Revenue 19.22  33.43 
Research And Ddevelopement To Revenue 5.22  4.96 
Capex To Revenue 0.09  0.09 
Revenue Per Share 2.30  3.12 
Ebit Per Revenue(18.81)(19.75)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Kala Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kala Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kala Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kala Pharmaceuticals Stock:
How To Invest In Kala
Details
Is Kala Stock a good investment?
Details
What is Kala Pharmaceuticals' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Kala Pharmaceuticals Correlation against competitors.
For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kala Pharmaceuticals. Expected growth trajectory for Kala significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Kala Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(5.73)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.66)
Return On Equity
(7.08)
The market value of Kala Pharmaceuticals is measured differently than its book value, which is the value of Kala that is recorded on the company's balance sheet. Investors also form their own opinion of Kala Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kala Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kala Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kala Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Kala Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Kala Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Kala Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY